Search Results - Rogier Mous

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES by Kim Linton, Jeanette Doorduijn, Dima El-Sharkawi, Rogier Mous, Francesco Forconi, David Lewis, Mary Gleeson, John Riches, Pam Mckay, Wendy Stevens, Sarah G Injac, Graham P Collins

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  2. 2

    P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP by Diana Al-Sarayfi, Mirian Brink, Martine E. D. Chamuleau, Rolf Brouwer, Roos van Rijn, Djamila Issa, Wendy Deenik, Gerwin Huls, Rogier Mous, Joost S.P. Vermaat, Josee M. Zijlstra, Tom van Meerten, Marcel Nijland

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  3. 3

    S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL by Aleksandra Urban, Johanne Hermansen, Yanping Yin, Weikaixin Kong, Rebecca Teglgaard, Christian Brieghel, Sabina Kersting, Geir E. Tjønnfjord, Mark-David Levin, Hoa T. T. Tran, Mattias Mattsson, Juha Ranti, Gerrit-Jan Veldhuis, Caspar Da Cunha-Bang, Rogier Mous, Julie Dubois, Arnon Kater, Carsten Niemann, Tero Aittokallio, Sigrid Skånland

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  4. 4

    S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL by Arnon Kater, Julie Dubois, Christian Brieghel, Sabina Kersting, Lisbeth Enggaard, Gerrit Veldhuis, Rogier Mous, Clemens Mellink, Johan Dobber, Christian Poulsen, Caspar Da Cunha-Bang, Hendrik Fredriksen, Ann Janssens, Ida Schjodt, Ellen Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa Tran, Kazem Nasserinejad, Mark-David Levin, Carsten Niemann

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  5. 5

    Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA by Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A. A. Bult, Martijn M. Terpstra, Pim G. N. J. Mutsaers, Wendy B. C. Stevens, Rogier Mous, Joost S. P. Vermaat, Martine E. D. Chamuleau, Walter Noordzij, Erik A. M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra, Wouter J. Plattel, Anke van den Berg, Marcel Nijland

    Published in Journal of Hematology & Oncology (2023-09-01)
    Get full text
    Article


  6. 6

    Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial by Carsten U. Niemann, Julie Dubois, Kazem Nasserinejad, Caspar da Cunha-Bang, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H.M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Johan A. Dobber, Christian B. Poulsen, Wida Razawy, René Hollestein, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Arnon P. Kater, Mark-David Levin

    Published in Blood Advances (2025-08-01)
    Get full text
    Article


  7. 7

    Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial by Martine E.D. Chamuleau, Coreline N. Burggraaff, Marcel Nijland, Katerina Bakunina, Rogier Mous, Pieternella J. Lugtenburg, Daan Dierickx, Gustaaf W. van Imhoff, Joost S.P. Vermaat, Erik A.F. Marijt, Otto Visser, Caroline Mandigers, Yavuz M. Bilgin, Aart Beeker, Mark F. Durian, Bas van Rees, Lara H. Bohmer, Lidwine W. Tick, Rinske S. Boersma, Tjeerd J.F. Snijders, Harry C. Schouten, Harry R. Koene, Eva de Jongh, Nathalie Hijmering, Arjan Diepstra, Anke van den Berg, Anne I.J. Arens, Julia Huijbregts, Otto Hoekstra, Josee M. Zijlstra, Daphne de Jong, Marie José Kersten

    Published in Haematologica (2019-12-01)
    Get full text
    Article


  8. 8

    Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP by Marcel Nijland, Djamila E. Issa, Johanna A. A. Bult, Dries Deeren, Gerjo A. Velders, Marten R. Nijziel, Yorick Sandberg, Vibeke Vergote, Margriet Oosterveld, Rob Fijnheer, Rolf E. Brouwer, Rinske S. Boersma, Kalung Wu, Laurens Nieuwenhuizen, Joost S. P. Vermaat, Roel J. W. van Kampen, Wim E. Terpstra, Sylvia Snauwaert, Marjolein W. van der Poel, Eva de Jongh, Marc F. Durian, Leonie Strobbe, Aart Beeker, Alain Gadisseur, Roos S. van Rijn, Otto Visser, Jeanette K. Doorduijn, Tjeerd J. F. Snijders, Matthijs H. Silbermann, Daphne de Jong, Martine Chamuleau, Rogier Mous, Hilde Jalving, Heleen Visser-Wisselaar, Sonja Jansen van de Bergh, Gerben J. C. Zwezerijnen, Edwin Bremer, Mirian Brink, Arjan Diepstra, Dana A. Chitu, Harry R. Koene, Josée M. Zijlstra

    Published in Blood Advances (2025-07-01)
    Get full text
    Article


Search Tools: